Grifols reported third-quarter 2026 revenue of EUR 2.04 billion, up 8.4% at constant currency. Net profit rose 27.9% to EUR 162 million. Revenue for the first nine months of the year totaled EUR 5.614 billion.
Biopharma revenue grew 10.3% at constant currency in the third quarter, largely on strong demand for immunoglobulins. Albumin revenue declined 13.2%, amid regulatory factors and high inventory levels in China.
The adjusted EBITDA margin expanded to 26.4% in the quarter. Grifols reduced its net leverage ratio to below 4x. Free cash flow before M&A reached EUR 298 million for the first nine months, a significant improvement.